SynthesisBioscience reports2019
Probiotics combined with aminosalicylic acid affiliates remission of ulcerative colitis: a meta-analysis of randomized controlled trial.
Synthesis in Bioscience reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 4 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Efficacy and safety of dietary supplements for the treatment of ulcerative colitis, a network meta-analysis.Frontiers in medicine · 2026Pooled it
- Pooled it
- Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in inflammatory bowel disease: a systematic review and meta-analysis.European journal of nutrition · 2021Pooled it
- Pooled it
- Probiotic drug interactions in ulcerative colitis: a microbiota and metabolite perspective.Frontiers in microbiology · 2026Review
- Probiotics and inflammatory bowel disease: an umbrella meta-analysis of relapse, recurrence, and remission outcomes.Nutrition & metabolism · 2025Review
- Ulcerative colitis: molecular insights and intervention therapy.Molecular biomedicine · 2024Review
- Anti-Inflammatory and Anti-Oxidant Impacts of Lentinan Combined with Probiotics in Ulcerative Colitis.Molecular biotechnology · 2024Article
- Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches.Microbiome research reports · 2023Article
- Biomarkers of ulcerative colitis disease activity CXCL1, CYP2R1, LPCAT1, and NEU4 and their relationship to immune infiltrates.Scientific reports · 2023Article
- Review
- Review
- Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches.Biomedicines · 2022Review
- Nutritional Treatment in Crohn's Disease.Nutrients · 2021Review
- Role of Short Chain Fatty Acids and Apolipoproteins in the Regulation of Eosinophilia-Associated Diseases.International journal of molecular sciences · 2021Review
- Efficacy of Dietary Supplements in Inflammatory Bowel Disease and Related Autoimmune Diseases.Nutrients · 2020Review
- Discovery of a Novel Multi-Strains Probiotic Formulation with Improved Efficacy toward Intestinal Inflammation.Nutrients · 2020Article
- Review
- Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases.Digestive diseases and sciences · 2020Review
- The Efficacy and Safety of Mesalamine and Probiotics in Mild-to-Moderate Ulcerative Colitis: A Systematic Review and Meta-Analysis.Evidence-based complementary and alternative medicine : eCAM · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We conducted a meta-analysis to evaluate the effect of probiotic combined with aminosalicylic on induction remission maintenance treatment of ulcerative colitis (UC). We conducted systematic searches in several Chinese and English databases from inception to June 2018, screening randomized controlled trials about effect of probiotics combined with aminosalicylic acid on UC. The evaluation indicator was the rate of remission. The relative risk (RR) and 95% confidence interval (CI) were calculated. A total of 27 studies with 1942 patients were included. The results indicated that the remission rate was significantly higher in the group using probiotics combined with aminosalicylic acid than that in the group using aminosalicylic acid alone (RR = 1.40, 95% CI: 1.27-1.53,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.